

Esther G C Troost

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2179557/publications.pdf>

Version: 2024-02-01

176
papers

7,494
citations

71061

41
h-index

64755

79
g-index

191
all docs

191
docs citations

191
times ranked

8643
citing authors

#	ARTICLE	IF	CITATIONS
1	The European Particle Therapy Network (EPTN) consensus on the follow-up of adult patients with brain and skull base tumours treated with photon or proton irradiation. <i>Radiotherapy and Oncology</i> , 2022, 168, 241-249.	0.3	11
2	Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1386-1406.	3.3	24
3	Experimental validation of 4D log file-based proton dose reconstruction for interplay assessment considering amplitude-sorted 4DCTs. <i>Medical Physics</i> , 2022, 49, 3538-3549.	1.6	8
4	Development of explanatory movies for the delineation of new organs at risk in neuro-oncology. <i>Clinical and Translational Radiation Oncology</i> , 2022, 33, 112-114.	0.9	2
5	Pre-treatment visualization of predicted radiation-induced acute alopecia in brain tumour patients. <i>Clinical and Translational Radiation Oncology</i> , 2022, 33, 106-111.	0.9	1
6	Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P). <i>Cancers</i> , 2022, 14, 2073.	1.7	7
7	Treatment planning comparison in the PROTECT-trial randomising proton versus photon beam therapy in oesophageal cancer: Results from eight European centres. <i>Radiotherapy and Oncology</i> , 2022, 172, 32-41.	0.3	2
8	Assessment of gene expressions from squamous cell carcinoma of the head and neck to predict radiochemotherapy-related xerostomia and dysphagia. <i>Acta Oncologica</i> , 2022, 61, 856-863.	0.8	4
9	Analysis of MRI and CT-based radiomics features for personalized treatment in locally advanced rectal cancer and external validation of published radiomics models. <i>Scientific Reports</i> , 2022, 12, .	1.6	16
10	Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase III clinical trial PaCa-DD-041 (Eudra-CT) Tj ETQq0 0 0 10BT /Overdeck 10 Tf		
11	Role of radiotherapy in the management of brain metastases of NSCLC – Decision criteria in clinical routine. <i>Radiotherapy and Oncology</i> , 2021, 154, 269-273.	0.3	11
12	Proposal for the delineation of neoadjuvant target volumes in oesophageal cancer. <i>Radiotherapy and Oncology</i> , 2021, 156, 102-112.	0.3	19
13	Technical Note: ADAM PETER – An anthropomorphic, deformable and multimodality pelvis phantom with positron emission tomography extension for radiotherapy. <i>Medical Physics</i> , 2021, 48, 1624-1632.	1.6	7
14	Definition and validation of a radiomics signature for loco-regional tumour control in patients with locally advanced head and neck squamous cell carcinoma. <i>Clinical and Translational Radiation Oncology</i> , 2021, 26, 62-70.	0.9	8
15	Toxicity of L19-Interleukin 2 Combined with Stereotactic Body Radiation Therapy: A Phase 1 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1421-1430.	0.4	7
16	Dose-escalated simultaneously integrated boost photon or proton therapy in pancreatic cancer in an in-silico study: Gastrointestinal organs remain critical. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 24-31.	0.9	2
17	Generation of biological hypotheses by functional imaging links tumor hypoxia to radiation induced tissue inflammation/glucose uptake in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2021, 155, 204-211.	0.3	5
18	Do We Need Complex Image Features to Personalize Treatment of Patients with Locally Advanced Rectal Cancer?. <i>Lecture Notes in Computer Science</i> , 2021, , 775-785.	1.0	2

#	ARTICLE	IF	CITATIONS
19	MR Image Changes of Normal-Appearing Brain Tissue after Radiotherapy. <i>Cancers</i> , 2021, 13, 1573.	1.7	17
20	Modelling of late side-effects following cranial proton beam therapy. <i>Radiotherapy and Oncology</i> , 2021, 157, 15-23.	0.3	6
21	The ROCOCO performance scoring system translates dosimetric differences into clinically relevant endpoints: Comparing IMPT to VMAT in an example pilocytic astrocytoma dataset. <i>Clinical and Translational Radiation Oncology</i> , 2021, 28, 32-38.	0.9	2
22	Value of PET imaging for radiation therapy. <i>Nuklearmedizin - NuclearMedicine</i> , 2021, 60, 326-343.	0.3	2
23	Identification of patient benefit from proton beam therapy in brain tumour patients based on dosimetric and NTCP analyses. <i>Radiotherapy and Oncology</i> , 2021, 160, 69-77.	0.3	8
24	Value of PET imaging for radiation therapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1-23.	1.0	16
25	Update of the EPTN atlas for CT- and MR-based contouring in Neuro-Oncology. <i>Radiotherapy and Oncology</i> , 2021, 160, 259-265.	0.3	32
26	Role of Postoperative Radiotherapy in the Management for Resected NSCLC – Decision Criteria in Clinical Routine Pre- and Post-LungART. <i>Clinical Lung Cancer</i> , 2021, 22, 579-586.	1.1	9
27	The impact of anatomical changes during photon or proton based radiation treatment on tumor dose in glioblastoma dose escalation trials. <i>Radiotherapy and Oncology</i> , 2021, 164, 202-208.	0.3	0
28	The role of postoperative thoracic radiotherapy and prophylactic cranial irradiation in early stage small cell lung cancer: Patient selection among ESTRO experts. <i>Radiotherapy and Oncology</i> , 2020, 145, 45-48.	0.3	9
29	How public health services pay for radiotherapy in Europe: an ESTRO – HERO analysis of reimbursement. <i>Lancet Oncology</i> , The, 2020, 21, e42-e54.	5.1	45
30	Quantification of plan robustness against different uncertainty sources for classical and anatomical robust optimized treatment plans in head and neck cancer proton therapy. <i>British Journal of Radiology</i> , 2020, 93, 20190573.	1.0	7
31	Photons or protons for reirradiation in (non-)small cell lung cancer: Results of the multicentric ROCOCO <i>in silico</i> study. <i>British Journal of Radiology</i> , 2020, 93, 20190879.	1.0	13
32	2D and 3D convolutional neural networks for outcome modelling of locally advanced head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 15625.	1.6	34
33	National societies' needs as assessed by the ESTRO National Societies Committee survey: A European perspective. <i>Radiotherapy and Oncology</i> , 2020, 151, 176-181.	0.3	3
34	The role of computational methods for automating and improving clinical target volume definition. <i>Radiotherapy and Oncology</i> , 2020, 153, 15-25.	0.3	31
35	Dose dependent cerebellar atrophy in glioma patients after radio(chemo)therapy. <i>Radiotherapy and Oncology</i> , 2020, 150, 262-267.	0.3	12
36	Comprehensive Analysis of Tumour Sub-Volumes for Radiomic Risk Modelling in Locally Advanced HNSCC. <i>Cancers</i> , 2020, 12, 3047.	1.7	19

#	ARTICLE	IF	CITATIONS
37	Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy. <i>Radiotherapy and Oncology</i> , 2020, 149, 189-196.	0.3	41
38	Investigation of inter-fraction target motion variations in the context of pencil beam scanned proton therapy in non-small cell lung cancer patients. <i>Medical Physics</i> , 2020, 47, 3835-3844.	1.6	16
39	Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. <i>BMC Cancer</i> , 2020, 20, 557.	1.1	29
40	The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. <i>Radiology</i> , 2020, 295, 328-338.	3.6	1,869
41	Proton therapy special feature: introductory editorial. <i>British Journal of Radiology</i> , 2020, 93, 20209004.	1.0	9
42	Refinement of the Hounsfield look-up table by retrospective application of patient-specific direct proton stopping-power prediction from dual-energy CT. <i>Medical Physics</i> , 2020, 47, 1796-1806.	1.6	15
43	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. <i>Radiotherapy and Oncology</i> , 2020, 147, 227-228.	0.3	9
44	Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer – Decision criteria in routine practise. <i>Radiotherapy and Oncology</i> , 2020, 150, 26-29.	0.3	13
45	CT-based attenuation correction of whole-body radiotherapy treatment positioning devices in PET/MRI hybrid imaging. <i>Physics in Medicine and Biology</i> , 2020, 65, 23NT02.	1.6	4
46	T-Staging and Target Volume Definition by Imaging in Head and Neck Tumors. <i>Medical Radiology</i> , 2020, , 169-181.	0.0	0
47	Development and validation of NTCP models for acute side-effects resulting from proton beam therapy of brain tumours. <i>Radiotherapy and Oncology</i> , 2019, 130, 164-171.	0.3	27
48	CT imaging during treatment improves radiomic models for patients with locally advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2019, 130, 10-17.	0.3	44
49	Reply to Piet R. Dirix, Carole Mercier, and Luc Y. Dirix's Letter to the Editor re: Fabian Lohaus, Klaus ZÄ¶phel, Steffen LÄ¶ck, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? <i>Eur Urol</i> 2019;75:548Ä¶51. <i>European Urology</i> , 2019, 76, e103-e104.	0.9	0
50	Reduced diffusion in normal appearing white matter of glioma patients following radio(chemo)therapy. <i>Radiotherapy and Oncology</i> , 2019, 140, 110-115.	0.3	21
51	Inter-observer variability in target delineation increases during adaptive treatment of head-and-neck and lung cancer. <i>Acta OncolÄ¶gica</i> , 2019, 58, 1378-1385.	0.8	24
52	Is reducing irradiated margins key to improving outcomes for radiotherapy?. <i>Lancet Oncology</i> , The, 2019, 20, 1208-1210.	5.1	2
53	Including anatomical variations in robust optimization for head and neck proton therapy can reduce the need of adaptation. <i>Radiotherapy and Oncology</i> , 2019, 131, 127-134.	0.3	42
54	Assessing robustness of radiomic features by image perturbation. <i>Scientific Reports</i> , 2019, 9, 614.	1.6	166

#	ARTICLE	IF	CITATIONS
55	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019, 133, 163-166.	0.3	24
56	Contact of a tumour with the pleura is not associated with regional recurrence following stereotactic ablative radiotherapy for early stage non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2019, 131, 120-126.	0.3	3
57	Comparison of pancreatic respiratory motion management with three abdominal corsets for particle radiation therapy: Case study. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 111-119.	0.8	13
58	Detectability and structural stability of a liquid fiducial marker in fresh ex vivo pancreas tumour resection specimens on CT and 3T MRI. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 756-763.	1.0	4
59	Challenges and caveats of a multi-center retrospective radiomics study: an example of early treatment response assessment for NSCLC patients using FDG-PET/CT radiomics. <i>PLoS ONE</i> , 2019, 14, e0217536.	1.1	38
60	Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019, 135, 74-77.	0.3	14
61	Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis. <i>Acta Oncologica</i> , 2019, 58, 916-925.	0.8	11
62	Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2019, 135, 43-50.	0.3	25
63	Dual-energy CT for automatic organs-at-risk segmentation in brain-tumor patients using a multi-atlas and deep-learning approach. <i>Scientific Reports</i> , 2019, 9, 4126.	1.6	29
64	Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients. <i>Clinical and Translational Radiation Oncology</i> , 2019, 15, 108-112.	0.9	9
65	Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo LacNAc+ Monocytes in Rectal Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 602.	2.2	8
66	Utility of fiducial markers for target positioning in proton radiotherapy of oesophageal carcinoma. <i>Radiotherapy and Oncology</i> , 2019, 133, 28-34.	0.3	8
67	Successful immunotherapy and irradiation in a HIV-positive patient with metastatic Merkel cell carcinoma. <i>Clinical and Translational Radiation Oncology</i> , 2019, 15, 42-45.	0.9	10
68	Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?. <i>European Urology</i> , 2019, 75, 548-551.	0.9	36
69	Dose-guided patient positioning in proton radiotherapy using multicriteria-optimization. <i>Zeitschrift Fur Medizinische Physik</i> , 2019, 29, 216-228.	0.6	19
70	Reply to Laprie A. et al. <i>Radiotherapy and Oncology</i> , 2019, 130, 194.	0.3	0
71	FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients. <i>Radiotherapy and Oncology</i> , 2019, 130, 97-103.	0.3	14
72	Intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: results of a multicentric <i>in silico</i> ROCOCO trial. <i>Acta Oncologica</i> , 2019, 58, 57-65.	0.8	20

#	ARTICLE	IF	CITATIONS
73	Photon vs. proton radiochemotherapy: Effects on brain tissue volume and perfusion. <i>Radiotherapy and Oncology</i> , 2018, 128, 121-127.	0.3	48
74	Evidence on the efficacy of primary radiosurgery or stereotactic radiotherapy for drug-resistant non-neoplastic focal epilepsy in adults: A systematic review. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2018, 55, 83-92.	0.9	10
75	Relative biological effectiveness in proton beam therapy – Current knowledge and future challenges. <i>Clinical and Translational Radiation Oncology</i> , 2018, 9, 35-41.	0.9	96
76	Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations – Chances and Challenges. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 529-541.	3.3	11
77	Retrospective assessment of MRI-based volumetric changes of normal tissues in glioma patients following radio(chemo)therapy. <i>Clinical and Translational Radiation Oncology</i> , 2018, 8, 17-21.	0.9	14
78	Prognostic Value of Head and Neck Tumor Proliferative Sphericity From ^3H -Deoxy- ^3H -[^{18}F] Fluorothymidine Positron Emission Tomography. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2018, 2, 33-40.	2.7	12
79	The EPTN consensus-based atlas for CT- and MR-based contouring in neuro-oncology. <i>Radiotherapy and Oncology</i> , 2018, 128, 37-43.	0.3	80
80	Photons, protons or carbon ions for stage I non-small cell lung cancer – Results of the multicentric ROCOCO in silico study. <i>Radiotherapy and Oncology</i> , 2018, 128, 139-146.	0.3	32
81	The posterior cerebellum, a new organ at risk?. <i>Clinical and Translational Radiation Oncology</i> , 2018, 8, 22-26.	0.9	23
82	Comparison of different treatment planning approaches for intensity-modulated proton therapy with simultaneous integrated boost for pancreatic cancer. <i>Radiation Oncology</i> , 2018, 13, 228.	1.2	14
83	The role of functional imaging in lung cancer. <i>Clinical and Translational Imaging</i> , 2018, 6, 441-447.	1.1	1
84	External validation of an NTCP model for acute esophageal toxicity in locally advanced NSCLC patients treated with intensity-modulated (chemo-)radiotherapy. <i>Radiotherapy and Oncology</i> , 2018, 129, 249-256.	0.3	8
85	Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus. <i>Radiotherapy and Oncology</i> , 2018, 128, 26-36.	0.3	112
86	Prospective data registration and clinical trials for particle therapy in Europe. <i>Radiotherapy and Oncology</i> , 2018, 128, 9-13.	0.3	20
87	Applicability of a prognostic CT-based radiomic signature model trained on stage I-III non-small cell lung cancer in stage IV non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 124, 6-11.	0.9	39
88	^{18}F -fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) – A prospective externally validated study. <i>PLoS ONE</i> , 2018, 13, e0192859.	1.1	57
89	Modeling patterns of anatomical deformations in prostate patients undergoing radiation therapy with an endorectal balloon. , 2017, , .		1
90	Individualized early death and long-term survival prediction after stereotactic radiosurgery for brain metastases of non-small cell lung cancer: Two externally validated nomograms. <i>Radiotherapy and Oncology</i> , 2017, 123, 189-194.	0.3	29

#	ARTICLE	IF	CITATIONS
91	Nodal recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: Incidence and proposed risk factors. <i>Cancer Treatment Reviews</i> , 2017, 56, 8-15.	3.4	33
92	Inclusion of Incidental Radiation Dose to the Cardiac Atria and Ventricles Does Not Improve the Prediction of Radiation Pneumonitis in Advanced-Stage Non-Small Cell Lung Cancer Patients Treated With Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 434-441.	0.4	16
93	The clinical target volume in lung, head-and-neck, and esophageal cancer: Lessons from pathological measurement and recurrence analysis. <i>Clinical and Translational Radiation Oncology</i> , 2017, 3, 1-8.	0.9	12
94	P2.05-014 Sites of Recurrent Disease in SCLC Patients Treated with Radiochemotherapy - Is Selective Nodal Irradiation Safe?. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1038-S1039.	0.5	0
95	OA09.06 Metformin Use during Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2017, 12, S278-S279.	0.5	0
96	Esophageal wall dose-surface maps do not improve the predictive performance of a multivariable NTCP model for acute esophageal toxicity in advanced stage NSCLC patients treated with intensity-modulated (chemo-)radiotherapy. <i>Physics in Medicine and Biology</i> , 2017, 62, 3668-3681.	1.6	10
97	Comparison of toxicity and outcome in advanced stage non-small cell lung cancer patients treated with intensity-modulated (chemo-)radiotherapy using IMRT or VMAT. <i>Radiotherapy and Oncology</i> , 2017, 122, 295-299.	0.3	31
98	A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling. <i>Scientific Reports</i> , 2017, 7, 13206.	1.6	163
99	Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging. <i>Radiotherapy and Oncology</i> , 2017, 124, 533-540.	0.3	123
100	Therapeutic options to overcome tumor hypoxia in radiation oncology. <i>Clinical and Translational Imaging</i> , 2017, 5, 455-464.	1.1	6
101	Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2017, 7, 36-42.	0.9	9
102	[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 8-16.	3.3	20
103	Session 39: Modelling and simulation III. <i>Biomedizinische Technik</i> , 2017, 62, .	0.9	0
104	Impact of robust treatment planning on single- and multi-field optimized plans for proton beam therapy of unilateral head and neck target volumes. <i>Radiation Oncology</i> , 2017, 12, 190.	1.2	25
105	Impact of pre- and early per-treatment FDG-PET based dose-escalation on local tumour control in fractionated irradiated FaDu xenograft tumours. <i>Radiotherapy and Oncology</i> , 2016, 121, 447-452.	0.3	8
106	Prognostic value of blood-biomarkers related to hypoxia, inflammation, immune response and tumour load in non-small cell lung cancer – A survival model with external validation. <i>Radiotherapy and Oncology</i> , 2016, 119, 487-494.	0.3	32
107	Vertebral fractures – An underestimated side-effect in patients treated with radio(chemo)therapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 421-423.	0.3	8
108	The Diagnostic Value of MR Imaging in Determining the Lymph Node Status of Patients with Non-Small Cell Lung Cancer: A Meta-Analysis. <i>Radiology</i> , 2016, 281, 86-98.	3.6	34

#	ARTICLE	IF	CITATIONS
109	Is selective nodal irradiation in non-small cell lung cancer still safe when using IMRT? Results of a prospective cohort study. <i>Radiotherapy and Oncology</i> , 2016, 121, 322-327.	0.3	12
110	Benefit of particle therapy in re-irradiation of head and neck patients. Results of a multicentric in silico ROCOCO trial. <i>Radiotherapy and Oncology</i> , 2016, 121, 387-394.	0.3	46
111	PRONTOX " proton therapy to reduce acute normal tissue toxicity in locally advanced non-small-cell lung carcinomas (NSCLC): study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 543.	0.7	20
112	FMISO as a Biomarker for Clinical Radiation Oncology. <i>Recent Results in Cancer Research</i> , 2016, 198, 189-201.	1.8	8
113	Evaluation of tumour hypoxia during radiotherapy using [18F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2139-2146.	3.3	51
114	Increasing the Therapeutic Ratio of Stereotactic Ablative Radiotherapy by Individualized Isotoxic Dose Prescription. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv305.	3.0	34
115	Emerging Role of MRI for Radiation Treatment Planning in Lung Cancer. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, NP47-NP60.	0.8	12
116	Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 453-459.	0.3	68
117	Early Weight Loss during Chemoradiotherapy Has a Detrimental Impact on Outcome in NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 873-879.	0.5	38
118	Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 240-248.	3.3	64
119	Evaluating the use of optimally respiratory gated 18F-FDG-PET in target volume delineation and its influence on radiation doses to the organs at risk in non-small-cell lung cancer patients. <i>Nuclear Medicine Communications</i> , 2016, 37, 66-73.	0.5	8
120	The effect of SUV discretization in quantitative FDG-PET Radiomics: the need for standardized methodology in tumor texture analysis. <i>Scientific Reports</i> , 2015, 5, 11075.	1.6	318
121	PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes. <i>Radiotherapy and Oncology</i> , 2015, 116, 281-286.	0.3	64
122	Imaging-Based Treatment Adaptation in Radiation Oncology. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1922-1929.	2.8	27
123	Imaging of tumour hypoxia and metabolism in patients with head and neck squamous cell carcinoma. <i>Acta Oncol³gica</i> , 2015, 54, 1378-1384.	0.8	17
124	Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects. <i>Clinical Cancer Research</i> , 2015, 21, 1151-1160.	3.2	79
125	Validation of functional imaging as a biomarker for radiation treatment response. <i>British Journal of Radiology</i> , 2015, 88, 20150014.	1.0	22
126	In response to "Histopathologic validation of 3-deoxy-3-18F-fluorothymidine PET for detecting tumour repopulation during fractionated radiotherapy in human FaDu squamous cell carcinoma in nude mice". <i>Radiotherapy and Oncology</i> , 2015, 114, 417-418.	0.3	0

#	ARTICLE	IF	CITATIONS
127	A teaching intervention in a contouring dummy run—improved target volume delineation in locally advanced non-small cell lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 525-533.	1.0	31
128	PET in the management of locally advanced and metastatic NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 395-407.	12.5	75
129	Multivariable normal-tissue complication modeling of acute esophageal toxicity in advanced stage non-small cell lung cancer patients treated with intensity-modulated (chemo-)radiotherapy. <i>Radiotherapy and Oncology</i> , 2015, 117, 49-54.	0.3	55
130	Weekly kilovoltage cone-beam computed tomography for detection of dose discrepancies during (chemo)radiotherapy for head and neck cancer. <i>Acta Oncologica</i> , 2015, 54, 1483-1489.	0.8	10
131	Is integrated transit planar portal dosimetry able to detect geometric changes in lung cancer patients treated with volumetric modulated arc therapy?. <i>Acta Oncologica</i> , 2015, 54, 1501-1507.	0.8	16
132	Comparison of [18F]-FMISO, [18F]-FAZA and [18F]-HX4 for PET imaging of hypoxia — a simulation study. <i>Acta Oncologica</i> , 2015, 54, 1370-1377.	0.8	61
133	Preclinical Assessment of Efficacy of Radiation Dose Painting Based on Intratumoral FDG-PET Uptake. <i>Clinical Cancer Research</i> , 2015, 21, 5511-5518.	3.2	23
134	Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study. <i>European Journal of Cancer</i> , 2015, 51, 2534-2544.	1.3	50
135	Radiation-induced lung damage — Clinical risk profiles and predictive imaging on their way to risk-adapted individualized treatment planning?. <i>Radiotherapy and Oncology</i> , 2015, 117, 1-3.	0.3	21
136	Rapid Decline of Follicular Lymphoma-Associated Chylothorax after Low Dose Radiotherapy to Retroperitoneal Lymphoma Localization. <i>Case Reports in Hematology</i> , 2014, 2014, 1-5.	0.3	6
137	Patient selection for whole brain radiotherapy (WBRT) in a large lung cancer cohort: Impact of a new Dutch guideline on brain metastases. <i>Acta Oncologica</i> , 2014, 53, 945-951.	0.8	16
138	A qualitative synthesis of the evidence behind elective lymph node irradiation in oesophageal cancer. <i>Radiotherapy and Oncology</i> , 2014, 113, 166-174.	0.3	22
139	Particle Therapy for Non-Small Cell Lung Tumors: Where Do We Stand? A Systematic Review of the Literature. <i>Frontiers in Oncology</i> , 2014, 4, 292.	1.3	54
140	<i>In Vivo</i> Quantification of Hypoxic and Metabolic Status of NSCLC Tumors Using [18F]HX4 and [18F]FDG-PET/CT Imaging. <i>Clinical Cancer Research</i> , 2014, 20, 6389-6397.	3.2	81
141	Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 915-924.	3.3	31
142	Stereotactic ablative body radiotherapy combined with immunotherapy: Present status and future perspectives. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2014, 18, 391-395.	0.6	23
143	Epigenetics in radiotherapy: Where are we heading?. <i>Radiotherapy and Oncology</i> , 2014, 111, 168-177.	0.3	43
144	Molecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancer. <i>Acta Oncologica</i> , 2013, 52, 1257-1271.	0.8	50

#	ARTICLE	IF	CITATIONS
145	Characterization of tumor heterogeneity using dynamic contrast enhanced CT and FDG-PET in non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2013, 109, 65-70.	0.3	37
146	“Rapid Learning health care in oncology” – An approach towards decision support systems enabling customised radiotherapy. <i>Radiotherapy and Oncology</i> , 2013, 109, 159-164.	0.3	175
147	Definitive radiation therapy for treatment of laryngeal carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2013, 189, 834-841.	1.0	34
148	Locally advanced verrucous carcinoma of the oral cavity. <i>Strahlentherapie Und Onkologie</i> , 2013, 189, 894-898.	1.0	6
149	Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients. <i>Radiotherapy and Oncology</i> , 2013, 109, 100-106.	0.3	50
150	Hypoxia imaging with [18F]HX4 PET in NSCLC patients: Defining optimal imaging parameters. <i>Radiotherapy and Oncology</i> , 2013, 109, 58-64.	0.3	81
151	¹⁸ F-FLT PET During Radiotherapy or Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma Is an Early Predictor of Outcome. <i>Journal of Nuclear Medicine</i> , 2013, 54, 532-540.	2.8	111
152	First clinical results of adaptive radiotherapy based on 3D portal dosimetry for lung cancer patients with atelectasis treated with volumetric-modulated arc therapy (VMAT). <i>Acta Oncologica</i> , 2013, 52, 1484-1489.	0.8	36
153	Correlation between tumor oxygenation and 18F-fluoromisonidazole PET data simulated based on microvessel images. <i>Acta Oncologica</i> , 2013, 52, 1308-1313.	0.8	15
154	Prognostic value of metabolic metrics extracted from baseline positron emission tomography images in non-small cell lung cancer. <i>Acta Oncologica</i> , 2013, 52, 1398-1404.	0.8	44
155	¹⁸ F-FDG PET Early Response Evaluation of Locally Advanced Non-Small Cell Lung Cancer Treated with Concomitant Chemoradiotherapy. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1528-1534.	2.8	104
156	Balancing Radiation Pneumonitis Versus Locoregional Tumor Control in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, e35-e36.	0.5	0
157	Balancing Radiation Pneumonitis Versus Locoregional Tumor Control in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, e47.	0.5	0
158	Modelling and simulation of the influence of acute and chronic hypoxia on [¹⁸ F]fluoromisonidazole PET imaging. <i>Physics in Medicine and Biology</i> , 2012, 57, 1675-1684.	1.6	30
159	Individualized Dose Prescription for Hypofractionation in Advanced Non-Small-Cell Lung Cancer Radiotherapy: An in silico Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1596-1602.	0.4	31
160	² -Deoxy- ³ - ¹⁸ F-Fluorothymidine PET-Derived Proliferative Volume Predicts Overall Survival in High-Grade Glioma Patients. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1904-1910.	2.8	44
161	Treatment outcome and toxicity of intensity-modulated (chemo) radiotherapy in stage III non-small cell lung cancer patients. <i>Radiation Oncology</i> , 2012, 7, 150.	1.2	33
162	Modelling and simulation of [18F]fluoromisonidazole dynamics based on histology-derived microvessel maps. <i>Physics in Medicine and Biology</i> , 2011, 56, 2045-2057.	1.6	54

#	ARTICLE	IF	CITATIONS
163	Early identification of antigen-specific immune responses in vivo by [¹⁸ F]-labeled 3- ¹⁸ F-fluoro-3-deoxy-thymidine ([¹⁸ F]FLT) PET imaging. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18396-18399.	3.3	65
164	Histopathologic Validation of 3-Deoxy- ¹⁸ F-Fluorothymidine PET in Squamous Cell Carcinoma of the Oral Cavity. Journal of Nuclear Medicine, 2010, 51, 713-719.	2.8	23
165	PET of Hypoxia with ⁸⁹ Zr-Labeled cG250-F(ab ²) in Head and Neck Tumors. Journal of Nuclear Medicine, 2010, 51, 1076-1083.	2.8	98
166	Innovations in Radiotherapy Planning of Head and Neck Cancers: Role of PET. Journal of Nuclear Medicine, 2010, 51, 66-76.	2.8	73
167	Correlation of Segmented Metabolic Tumor Volume with Outcome - Letter. Clinical Cancer Research, 2010, 16, 1968-1968.	3.2	0
168	¹⁸ F-FLT PET/CT for Early Response Monitoring and Dose Escalation in Oropharyngeal Tumors. Journal of Nuclear Medicine, 2010, 51, 866-874.	2.8	147
169	Clinical evidence on PET-CT for radiation therapy planning in head and neck tumours. Radiotherapy and Oncology, 2010, 96, 328-334.	0.3	88
170	¹⁸ F-FDG and ¹⁸ F-FLT Do Not Discriminate Between Reactive and Metastatic Lymph Nodes in Oral Cancer. Journal of Nuclear Medicine, 2009, 50, 490-491.	2.8	11
171	Combined ¹⁸ F-FDG-PET/CT Imaging in Radiotherapy Target Delineation for Head-and-Neck Cancer. In: Guido et al. (Int J Radiat Oncol Biol Phys 2009;73:759-763). International Journal of Radiation Oncology Biology Physics, 2009, 74, 1629.	0.4	1
172	Correlation of [¹⁸ F]FMISO autoradiography and pimonidazole immunohistochemistry in human head and neck carcinoma xenografts. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1803-1811.	3.3	85
173	Intratumoral Spatial Distribution of Hypoxia and Angiogenesis Assessed by ¹⁸ F-FAZA and ¹²⁵ I-Gluco-RGD Autoradiography. Journal of Nuclear Medicine, 2008, 49, 1732.1-1732.	2.8	2
174	¹⁸ F-FLT PET Does Not Discriminate Between Reactive and Metastatic Lymph Nodes in Primary Head and Neck Cancer Patients. Journal of Nuclear Medicine, 2007, 48, 726-735.	2.8	142
175	Imaging hypoxia after oxygenation-modification: Comparing [¹⁸ F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. Radiotherapy and Oncology, 2006, 80, 157-164.	0.3	72
176	Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines. Radiotherapy and Oncology, 2005, 76, 194-199.	0.3	56